share_log

藥明合聯：將於2024年6月12日（星期三）舉行的股東週年大會代表委任表格

WUXI XDC: FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 12, 2024

Hong Kong Stock Exchange ·  May 21 18:06
Summary by Futu AI
药明合联生物技术有限公司（WUXI XDC）將於2024年6月12日舉行股東週年大會，地點為中國江蘇省無錫市。會議將審議包括接納2023年度經審核財務報表、董事會報告及獨立核數師報告在內的多項普通決議案。此外，會上還將進行董事的重選，包括李錦才博士、張靖偉先生和席曉捷先生。股東將授權董事會釐定董事酬金，續聘德勤會計師行為核數師，並審議2024年股份計劃。此外，股東大會還將授予董事一般授權以發行、配發及處理股份，以及購回公司股份。股東需於2024年6月10日前提交代表委任表格，以便在大會上表決。
药明合联生物技术有限公司（WUXI XDC）將於2024年6月12日舉行股東週年大會，地點為中國江蘇省無錫市。會議將審議包括接納2023年度經審核財務報表、董事會報告及獨立核數師報告在內的多項普通決議案。此外，會上還將進行董事的重選，包括李錦才博士、張靖偉先生和席曉捷先生。股東將授權董事會釐定董事酬金，續聘德勤會計師行為核數師，並審議2024年股份計劃。此外，股東大會還將授予董事一般授權以發行、配發及處理股份，以及購回公司股份。股東需於2024年6月10日前提交代表委任表格，以便在大會上表決。
PHARMACEUTICAL UNITED BIOTECHNOLOGY CO., LTD. (WUXI XDC) WILL HOLD ITS ANNUAL GENERAL MEETING ON JUNE 12, 2024 AT WUXI CITY, JIANGSU PROVINCE, CHINA. The meeting will consider a number of general resolutions including the adoption of the 2023 audited financial statements, the Board's report and the independent auditor's report. In addition, the re-election of directors will be held at the meeting, including Dr. Li Kam Chai, Mr. Zhang Jingwei and Mr. Shi Xiaojie. Shareholders will authorize the Board of Directors to determine the remuneration of directors, to renew the accounting officer of Deloitte as an acting auditor, and to review the 2024 share plan. IN ADDITION, THE GENERAL MEETING WILL GRANT THE DIRECTORS GENERAL AUTHORITY TO ISSUE, DISTRIBUTE AND PROCESS SHARES AND REPURCHASE SHARES OF THE COMPANY. Shareholders are required to submit the proxy form by 10 June 2024 in order to vote at the General Meeting.
PHARMACEUTICAL UNITED BIOTECHNOLOGY CO., LTD. (WUXI XDC) WILL HOLD ITS ANNUAL GENERAL MEETING ON JUNE 12, 2024 AT WUXI CITY, JIANGSU PROVINCE, CHINA. The meeting will consider a number of general resolutions including the adoption of the 2023 audited financial statements, the Board's report and the independent auditor's report. In addition, the re-election of directors will be held at the meeting, including Dr. Li Kam Chai, Mr. Zhang Jingwei and Mr. Shi Xiaojie. Shareholders will authorize the Board of Directors to determine the remuneration of directors, to renew the accounting officer of Deloitte as an acting auditor, and to review the 2024 share plan. IN ADDITION, THE GENERAL MEETING WILL GRANT THE DIRECTORS GENERAL AUTHORITY TO ISSUE, DISTRIBUTE AND PROCESS SHARES AND REPURCHASE SHARES OF THE COMPANY. Shareholders are required to submit the proxy form by 10 June 2024 in order to vote at the General Meeting.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.